GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tian'an Pharmaceutical Co TNPH · USD

N/A · US listing · 🇺🇸 United States

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Tian'an Pharmaceutical Co

Its shares trade under the ticker TNPH. It has been listed since 25 June 2007. In the fiscal year to 31 December 2023, it reported revenue of $142,840 and a net loss of $16,027. At that date it held total assets of $359,591 and shareholders' equity of −$70,504.

Tian'an Pharmaceutical Co. Ltd. develops, manufactures and sell the traditional Chinese herbal medicines and biological pharmaceuticals. The company is headquartered in Xi'An, Shaanxi. The company went IPO on 2007-06-25.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
25 Jun 2007

Leadership

Pay as last reported

  • Jianjun WengChief Executive Officer, Director, since 2003$5,095
  • Wei LiChief Financial and Accounting Officer
  • Andong JiaChief Administrative Officer
  • Mr. Huachu TangChief Investment Officer
  • Peng XiChief Marketing Officer
  • Mingqi SunChief Quality Officer
  • Hailiang XueChief Production Officer
  • Renhua WangSecretary
  • Jinming GaoDirector
  • Ning JiaDirector
  • Deshun LiDirector
  • Zhiguo MaDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Tian'an Pharmaceutical's traditional Chinese herbal medicines are popular in China.
  • The company's biological pharmaceuticals are well-regarded in the domestic market.
  • Xi'an headquarters provides strategic location in Shaanxi province.

Weaknesses

  • Limited international presence outside China.
  • Dependence on traditional Chinese medicine market segments.
  • No significant presence in global pharmaceutical markets.

Opportunities

  • Growing demand for traditional Chinese medicine in Asia.
  • Expansion into Southeast Asian markets for biological pharmaceuticals.
  • Increasing healthcare spending in China's urban areas.

Threats

  • Regulatory changes in China's pharmaceutical industry.
  • Competition from domestic pharmaceutical companies.
  • Economic slowdown affecting healthcare spending in China.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.